Value of Diagnostic tests to Predict Conversion to Alzheimer's Disease in Young and Old Patients with Amnestic Mild Cognitive Impairment
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Using the database of the Alzheimer's Disease Neuroimaging Initiative, we examined the value of neuropsychological assessment, structural magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) biomarkers, and FDG-PET scanning with respect to prediction of conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD). We tested the hypothesis that CSF biomarkers and FDG-PET would lose prognostic value when applied in patients older than 75 years, whereas MRI and neuropsychological testing would not. At baseline 175 patients had MCI, mostly amnestic. They were followed during a mean of 2.7 years, and 81 patients converted to AD after a mean of 1.6 years. Logistic regression analyses showed that neuropsychological assessment and MRI variables predicted conversion with 63 to 67% classification success both in patients younger and older than 75 years, while CSF biomarkers attained this success rate only in patients younger than 75 years. For FDG-PET, this rate was 57% in the total sample. We conclude that the diagnostic yield of different techniques in predicting conversion from MCI to AD is moderate, and that it is affected by age of the subject under study. MRI and neuropsychological assessment remain informative in patients older than 75 years, unlike CSF biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“This vulnerability of diagnostic methods to age effects is important, because 1) most AD patients are older than 75 years [10]; 2) the association between clinical dementia and neuropathological characteristics of AD is weaker at higher ages [11]; and 3 other brain diseases mimicking a clinical AD…”
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationMixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“Another, more theoretical implication of these findings is that the prevalence of AD in older age cohorts will probably be much lower than currently thought if CSF biomarkers are to play a prominent role in the definitions of the disease, as was recently proposed [23, 24].”
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis
Bäckman, L., Jones, S., Berger, A.-K., Laukka, E. J., & Small, B. J. (2005) · Neuropsychology · doi:10.1037/0894-4105.19.4.520 · Cited by 735
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462 · cited 1×
“A previous study on the ADNI sample reported conversion of 26% of MCI patients with abnormal CSF values versus 12% of MCI patients with normal CSF composition after about one year of follow-up [27].”
Schoenmaker, N., & Van Gool, W. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00884-1 · Cited by 86
Cited by
2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,635
2014 Alzheimer's disease facts and figures
Alzheimer's Association (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.001 · Cited by 1,020
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
Self-citationAdvances in the prevention of Alzheimer's disease and dementia
Solomon, A., Mangialasche, F., Richard, E., Andrieu, S., Bennett, D. A., Breteler, M., Fratiglioni, L., Hooshmand, B., Khachaturian, A. S., Schneider, L. S., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12178 · Cited by 319
FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: A longitudinal study
Initiative, O. B. O. A. D. N., Ou, Y.-N., Xu, W., Li, J.-Q., Guo, Y., Cui, M., Chen, K.-L., Huang, Y.-Y., Dong, Q., Tan, L., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0512-1 · Cited by 155
Metadata
- Authors
- Schmand, B., Initiative, F. T. A. D. N., Eikelenboom, P., & van Gool, W. A.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2012-03-30
- Volume
- 29
- Issue
- 3
- Pages
- 641-648
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1568421081
- Cited by
- 41
- References
- 10
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.